← FDA DRUG APPROVALS

FDA ANDA · ANDA040029

KIONEX

Sponsor: ANI PHARMS

APPLICATION
ANDA040029
TYPE
ANDA
ORIGINAL APPROVAL
1998-02-06
LATEST ACTION
2020-03-16
ROUTE
ORAL, RECTAL
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

KIONEXPrescription
SODIUM POLYSTYRENE SULFONATE 454GM/BOT · POWDER · ORAL, RECTAL

Approval history

2020-03-16Labeling · Supplement 17 · standardAP
2012-09-26Labeling · Supplement 16AP
2011-12-08Labeling · Supplement 15AP
1998-02-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →